<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098788</article-id><article-id pub-id-type="doi">10.7759/cureus.82773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology/Diabetes/Metabolism</subject></subj-group><subj-group><subject>Geriatrics</subject></subj-group><subj-group><subject>Orthopedics</subject></subj-group></article-categories><title-group><article-title>Compliance With Parathyroid Hormone Analog Medications at a Single Osteoporosis Treatment Center</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Johnson</surname><given-names>Andrea H</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Brennan</surname><given-names>Jane C</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Boudani</surname><given-names>Daniel</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Chapa</surname><given-names>Lauren</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kidd</surname><given-names>Gerald</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Turcotte</surname><given-names>Justin J</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Morganti</surname><given-names>Christina</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Orthopedics, Anne Arundel Medical Center, Annapolis, USA </aff><aff id="aff-2">
<label>2</label>
Orthopedic Research, Anne Arundel Medical Center, Annapolis, USA </aff><aff id="aff-3">
<label>3</label>
Orthopedic and Surgical Research, Anne Arundel Medical Center, Annapolis, USA </aff><aff id="aff-4">
<label>4</label>
Orthopedic Surgery, Anne Arundel Medical Center, Annapolis, USA </aff><author-notes><corresp id="cor1">
Andrea H. Johnson <email>ajohnson21@luminishealth.org</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>e82773</elocation-id><history><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Johnson et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Johnson et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/359666-compliance-with-parathyroid-hormone-analog-medications-at-a-single-osteoporosis-treatment-center">This article is available from https://www.cureus.com/articles/359666-compliance-with-parathyroid-hormone-analog-medications-at-a-single-osteoporosis-treatment-center</self-uri><abstract><p>Background</p><p>Osteoporosis is the most common metabolic bone disease and is more common in female patients and the elderly. The costs associated with osteoporotic fractures present a significant burden on the healthcare system. While effective pharmacologic therapy exists, treatment initiation and compliance remain&#x000a0;suboptimal, leading to increased morbidity. This study evaluated compliance with parathyroid hormone analogs and identified reasons for non-compliance.</p><p>Methods</p><p>This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022. Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide. The primary outcomes of interest were continued compliance with medication therapy&#x000a0;and reasons for non-compliance. The secondary outcome of interest was fracture rate. Univariate analyses were performed to identify differences between the two groups, and a Kaplan-Meier curve was generated to show overall compliance.</p><p>Results</p><p>The average treatment duration was 15.5 months (95% CI: 13.5-17.4 months); 54 (54%) patients completed the full 24-month medication course. Abaloparatide patients had higher rates of non-compliance than teriparatide patients (33 (56.9%) vs. 13 (31.0%); p=0.018) and had a significantly shorter time to non-compliance (4.1 &#x000b1; 4.6 vs. 8.8 &#x000b1; 6.4 months; p=0.027).&#x000a0;There was a significant difference in reason for non-compliance between early (&#x02264;3 months) and late non-compliant patients (p=0.001). About 19 (79.2%) patients were non-compliant early because of side effects, while 10 (45.5%) patients were non-compliant late because of financial reasons. There were no differences in fracture rates between the two groups.</p><p>Conclusion</p><p>More than half of the patients in this study completed the full two-year course of treatment, and the average duration of treatment was over 15 months. The overall fracture rate during and after treatment was low. Financial concerns and side effects were the most common reasons for non-compliance. An additional study would be needed to evaluate methods for improving patient compliance with parathyroid hormone analogs.</p></abstract><kwd-group kwd-group-type="author"><kwd>abaloparatide</kwd><kwd>medication compliance</kwd><kwd>osteoporosis</kwd><kwd>parathyroid hormone analog</kwd><kwd>teriparatide</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Osteoporosis is the most common metabolic bone disease in the world and is characterized by low bone mineral density, disrupted bone microarchitecture, decreased bone strength, and fracture [<xref rid="REF1" ref-type="bibr">1</xref>]. It is a significant public health issue, with the National Osteoporosis Foundation estimating that 43.4 million Americans have low bone mass and an additional 10.2 million have osteoporosis, contributing to more than two million osteoporosis-related fractures annually [<xref rid="REF2" ref-type="bibr">2</xref>]. Osteoporosis is more common in female patients and the elderly, and the costs associated with fracture care place a significant and increasing burden on the health system [<xref rid="REF3" ref-type="bibr">3</xref>]. In a study of women aged 55 and older, osteoporotic fractures accounted for more hospitalizations than myocardial infarction, stroke, or breast cancer [<xref rid="REF4" ref-type="bibr">4</xref>]. Despite the significant issues that osteoporosis presents, it remains a very undertreated condition even after osteoporotic fracture [<xref rid="REF5" ref-type="bibr">5</xref>]. In patients who initiate osteoporosis treatment, treatment compliance remains a significant issue [<xref rid="REF6" ref-type="bibr">6</xref>-<xref rid="REF10" ref-type="bibr">10</xref>].</p><p>There are a number of classes of medications to treat osteoporosis, along with a variety of administration timings and routes [<xref rid="REF1" ref-type="bibr">1</xref>,<xref rid="REF2" ref-type="bibr">2</xref>]. Parathyroid hormone analogs, including teriparatide and abaloparatide, are highly efficacious in patients who are at high risk for fracture [<xref rid="REF1" ref-type="bibr">1</xref>,<xref rid="REF11" ref-type="bibr">11</xref>,<xref rid="REF12" ref-type="bibr">12</xref>]. The recombinant parathyroid hormone stimulates bone formation and may improve the bone microarchitecture, though use of these medications is typically limited to a two-year course of treatment [<xref rid="REF1" ref-type="bibr">1</xref>,<xref rid="REF2" ref-type="bibr">2</xref>]. Typically, a course of these medications is followed by initiating an antiresorptive agent in order to prevent rapid bone loss, which is associated with medication discontinuation [<xref rid="REF11" ref-type="bibr">11</xref>]. Several studies have shown improved compliance with these medications compared with other classes of osteoporosis medications despite the fact that they require a daily self-administered injection [<xref rid="REF6" ref-type="bibr">6</xref>,<xref rid="REF10" ref-type="bibr">10</xref>,<xref rid="REF13" ref-type="bibr">13</xref>]. The purpose of this study was to evaluate patient compliance with teriparatide and abaloparatide over the two-year course of treatment in a single osteoporosis treatment clinic and to evaluate the differences between compliant and non-compliant patients&#x000a0;as well as the reasons for noncompliance.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This was a retrospective observational cohort study of patients referred to Anne Arundel Medical Center, Annapolis, USA, from December 2017 to December 2022. This was a single-institutional study using patient data obtained from patient records in the electronic health record (EHR). The purpose of this study was to identify treatment patterns and compliance for patients referred to a dedicated osteoporosis clinic.&#x000a0;</p><p>Study population</p><p>A total of 123 patients prescribed teriparatide or abaloparatide from December 2017 to December 2022 at a dedicated community-based osteoporosis treatment clinic were included, with 23 of these patients ultimately lost to follow-up. Of the 100 patients that remained, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.</p><p>Outcomes</p><p>The primary outcomes of interest were continued compliance with prescribed osteoporosis medication, reasons for non-compliance with medication, and early/late non-compliance. Non-compliance was defined as stopping the medication permanently. The secondary outcome of interest was fracture rate.</p><p>Independent variables</p><p>The independent variables of interest were age, sex, race, body mass index (BMI), insurance, smoking status, history of fragility fracture, use of assistive device, cognitive dysfunction, current regular exercise, daily calcium supplement, daily vitamin D supplement, any previous bone medications, chronic kidney disease, liver disease, diabetes, history of cancer, thyroid disease, autoimmune disease, and family history of osteoporosis.</p><p>Statistical analysis</p><p>A Kaplan-Meier survival curve was generated to show overall compliance. Patients were then divided into compliant or non-compliant based on their compliance with their prescribed medication. Differences in patient characteristics and history between compliant and non-compliant patients were compared using two-sided independent samples t-tests for continuous measures and chi-squared tests for categorical measures. Differences in rates of non-compliance, time to non-compliance, and reason for non-compliance were compared between patients prescribed teriparatide and those prescribed abaloparatide using two-sided independent samples t-tests and chi-squared tests for categorical measures. Non-compliant patients were divided into early (less than or equal to&#x000a0;three months) and late (greater than three months) non-compliance based on when they stopped taking their medication. Differences in patient characteristics and history, rates of non-compliance, time to non-compliance, and reason for non-compliance were compared between early and late non-compliant patients using two-sided independent samples t-tests and chi-squared tests for categorical measures. Finally, differences in fracture rates between compliant and non-compliant patients, early and late non-compliant patients, and teriparatide and abaloparatide patients were compared using chi-squared tests. All statistical analyses were performed using RStudio v4.2.2&#x000a0;(Posit, Boston, USA). Statistical significance was assessed at p&#x0003c;0.05.&#x000a0;</p></sec><sec sec-type="results"><title>Results</title><p>The average duration of treatment was 15.5 months (95% CI: 13.5 to 17.4 months). At 12 months, approximately 60% of patients remained on treatment. Overall, 54% of patients completed the full 24-month medication course (Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>Medication compliance analyzed using the Kaplan-Meir survival curve</title><p>The average treatment duration was 15.5 months (95% CI: 13.5 to 17.4 months). At 12 months, approximately 60% of patients remained on treatment. In total, 54% of patients completed the full 24-month medication regimen.</p></caption><graphic xlink:href="cureus-0017-00000082773-i01" position="float"/></fig><p>&#x000a0;There were no differences in patient characteristics or history between compliant and non-compliant patients (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Patient history and characteristics by medication compliance </title><p>All data presented as n (%) or mean &#x000b1; SD.</p><p>* indicates Fisher&#x02019;s exact test; t-score indicates two-sided t-test; X<sup>2</sup> indicates chi-squared test</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Patient Characteristic</td><td rowspan="1" colspan="1">Compliant (n=54)</td><td rowspan="1" colspan="1">Non-compliant (n=46)</td><td rowspan="1" colspan="1">Test Statistic&#x000a0;</td><td rowspan="1" colspan="1">P-value</td></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">64.3 &#x000b1; 8.8</td><td rowspan="1" colspan="1">63.6 &#x000b1; 5.6</td><td rowspan="1" colspan="1">t-score = 0.447</td><td rowspan="1" colspan="1">0.656</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td rowspan="1" colspan="1">24.8 &#x000b1; 6.0</td><td rowspan="1" colspan="1">26.1 &#x000b1; 6.8</td><td rowspan="1" colspan="1">t-score = -0.977</td><td rowspan="1" colspan="1">0.331</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.060*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Male</td><td rowspan="1" colspan="1">5 (9.3)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Female</td><td rowspan="1" colspan="1">49 (90.7)</td><td rowspan="1" colspan="1">46 (100)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Non-White race</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (4.3)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.198*</td></tr><tr><td rowspan="1" colspan="1">Insurance</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Private</td><td rowspan="1" colspan="1">34 (63.0)</td><td rowspan="1" colspan="1">22 (47.8)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 1.736</td><td rowspan="1" colspan="1">0.188</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Medicare</td><td rowspan="1" colspan="1">20 (37.0)</td><td rowspan="1" colspan="1">23 (50.0)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 1.215</td><td rowspan="1" colspan="1">0.270</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Medicaid</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Uninsured</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (2.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.460*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Smoking status</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.526*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Current</td><td rowspan="1" colspan="1">4 (7.4)</td><td rowspan="1" colspan="1">2 (4.3)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Former</td><td rowspan="1" colspan="1">17 (31.5)</td><td rowspan="1" colspan="1">11 (23.9)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Never</td><td rowspan="1" colspan="1">33 (61.1)</td><td rowspan="1" colspan="1">33 (71.7)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">History of fragility fracture</td><td rowspan="1" colspan="1">41 (75.9)</td><td rowspan="1" colspan="1">35 (76.1)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Any assistive device</td><td rowspan="1" colspan="1">5 (9.3)</td><td rowspan="1" colspan="1">6 (13.0)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.080</td><td rowspan="1" colspan="1">0.296</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Cognitive dysfunction</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (2.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.460*</td></tr><tr><td rowspan="1" colspan="1">Current regular exercise</td><td rowspan="1" colspan="1">40 (74.1)</td><td rowspan="1" colspan="1">40 (87.0)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 1.834</td><td rowspan="1" colspan="1">0.176</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Calcium supplement</td><td rowspan="1" colspan="1">34 (63.0)</td><td rowspan="1" colspan="1">23 (50.0)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 1.215</td><td rowspan="1" colspan="1">0.270</td></tr><tr><td rowspan="1" colspan="1">Vitamin D supplement</td><td rowspan="1" colspan="1">43 (79.6)</td><td rowspan="1" colspan="1">35 (76.1)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.034</td><td rowspan="1" colspan="1">0.854</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Previous bone medication</td><td rowspan="1" colspan="1">19 (35.2)</td><td rowspan="1" colspan="1">20 (43.5)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.419</td><td rowspan="1" colspan="1">0.521</td></tr><tr><td rowspan="1" colspan="1">Chronic kidney disease</td><td rowspan="1" colspan="1">1 (1.9)</td><td rowspan="1" colspan="1">1 (2.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Liver disease</td><td rowspan="1" colspan="1">1 (1.9)</td><td rowspan="1" colspan="1">1 (2.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr><td rowspan="1" colspan="1">Diabetes</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.200*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0; Diet controlled</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (2.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Medication controlled</td><td rowspan="1" colspan="1">2 (3.7)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Other</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (4.3)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; None</td><td rowspan="1" colspan="1">52 (96.3)</td><td rowspan="1" colspan="1">43 (93.5)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">History of cancer</td><td rowspan="1" colspan="1">13 (24.1)</td><td rowspan="1" colspan="1">8 (17.4)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.327</td><td rowspan="1" colspan="1">0.568</td></tr><tr><td rowspan="1" colspan="1">Thyroid disease</td><td rowspan="1" colspan="1">11 (20.4)</td><td rowspan="1" colspan="1">5 (10.9)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 1.036</td><td rowspan="1" colspan="1">0.309</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Autoimmune disease</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.811*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Rheumatoid arthritis</td><td rowspan="1" colspan="1">3 (5.6)</td><td rowspan="1" colspan="1">2 (4.3)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Systemic lupus</td><td rowspan="1" colspan="1">1 (1.9)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Other</td><td rowspan="1" colspan="1">3 (5.6)</td><td rowspan="1" colspan="1">1 (2.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Family history of osteoporosis</td><td rowspan="1" colspan="1">37 (68.5)</td><td rowspan="1" colspan="1">26 (56.5)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 1.062</td><td rowspan="1" colspan="1">0.303</td></tr><tr><td rowspan="1" colspan="1">Total number of visits</td><td rowspan="1" colspan="1">8.3 &#x000b1; 2.2</td><td rowspan="1" colspan="1">7.5 &#x000b1; 3.3</td><td rowspan="1" colspan="1">t-score = 1.357</td><td rowspan="1" colspan="1">0.179</td></tr></tbody></table></table-wrap><p>Abaloparatide patients had higher rates of non-compliance than teriparatide patients (56.9% vs. 31.0%; p=0.018) and had a significantly shorter time to non-compliance (4.1 &#x000b1; 4.6 months vs. 8.8 &#x000b1; 6.4; p=0.027).&#x000a0;The reasons for non-compliance were different between abaloparatide and teriparatide patients (p&#x0003c;0.001); 69.7% of abaloparatide patients were non-compliant due to side effects, while 69.2% of teriparatide patients were non-compliant due to financial reasons (Table <xref rid="TAB2" ref-type="table">2</xref>).</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Reasons for non-compliance by medication prescribed</title><p>All data presented as n (%) or mean &#x000b1; SD.&#x000a0;P-value &#x0003c;0.05 in bold.</p><p>* indicates Fisher&#x02019;s exact test; t-score indicates two-sided t-test; X<sup>2</sup> indicates chi-squared test; ** calculated for non-compliant patients only (n=46)</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">All Patients (n=100)</td><td rowspan="1" colspan="1">Teriparatide (n=42)</td><td rowspan="1" colspan="1">Abaloparatide (n=58)</td><td rowspan="1" colspan="1">Test Statistic</td><td rowspan="1" colspan="1">P-value</td></tr><tr><td rowspan="1" colspan="1">Non-compliant</td><td rowspan="1" colspan="1">46 (46.0)</td><td rowspan="1" colspan="1">13 (31.0)</td><td rowspan="1" colspan="1">33 (56.9)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 5.598</td><td rowspan="1" colspan="1">0.018</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Time to non-compliance (months)**</td><td rowspan="1" colspan="1">5.4 &#x000b1; 5.5</td><td rowspan="1" colspan="1">8.8 &#x000b1; 6.4</td><td rowspan="1" colspan="1">4.1 &#x000b1; 4.6</td><td rowspan="1" colspan="1">t-score = 4.060 &#x000a0;</td><td rowspan="1" colspan="1">0.027</td></tr><tr><td rowspan="1" colspan="1">Reason for non-compliance**</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Financial</td><td rowspan="1" colspan="1">14 (30.4)</td><td rowspan="1" colspan="1">9 (69.2)</td><td rowspan="1" colspan="1">5 (15.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Patient decision</td><td rowspan="1" colspan="1">3 (6.5)</td><td rowspan="1" colspan="1">2 (15.4)</td><td rowspan="1" colspan="1">1 (3.0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Provider switched</td><td rowspan="1" colspan="1">5 (10.9)</td><td rowspan="1" colspan="1">1 (7.7)</td><td rowspan="1" colspan="1">4 (12.1)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Side effects</td><td rowspan="1" colspan="1">24 (52.2)</td><td rowspan="1" colspan="1">1 (7.7)</td><td rowspan="1" colspan="1">23 (69.7)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>Of the 46 non-compliant patients, 52.2% were non-compliant early and 47.8% were non-compliant late. Late non-compliant patients, on average, had a higher BMI than early non-compliant patients (28.9 &#x000b1; 7.2 vs. 23.5 &#x000b1; 5.3; p=0.008), and there was a significant difference in reasons for non-compliance between early and late non-compliant patients (p=0.001). About 79.2% of early non-compliant patients were non-compliant because of side effects, while 45.5% of late non-compliant patients were non-compliant because of financial reasons (Table <xref rid="TAB3" ref-type="table">3</xref>).</p><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Patient characteristics and reasons for non-compliance (early vs. late non-compliance)</title><p>All data presented as n (%) or mean &#x000b1; SD. P-value &#x0003c;0.05 in bold.</p><p>* indicates Fisher&#x02019;s exact test; t-score indicates two-sided t-test; X<sup>2</sup> indicates chi-squared test</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Patient Characteristic</td><td rowspan="1" colspan="1">Early Non-compliance (&#x02264;3 months) (n=24)</td><td rowspan="1" colspan="1">Late Non-compliance (&#x0003e;3 months) (n=22)</td><td rowspan="1" colspan="1">Test Statistic &#x000a0;</td><td rowspan="1" colspan="1">P-value</td></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">62.8 &#x000b1;5.3</td><td rowspan="1" colspan="1">64.5 &#x000b1;5.9</td><td rowspan="1" colspan="1">t-score = -0.978</td><td rowspan="1" colspan="1">0.334</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td rowspan="1" colspan="1">23.5 &#x000b1; 5.3</td><td rowspan="1" colspan="1">28.9 &#x000b1; 7.2</td><td rowspan="1" colspan="1">t-score = -2.816</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Male</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Female</td><td rowspan="1" colspan="1">24 (100)</td><td rowspan="1" colspan="1">22 (100)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Non-White race</td><td rowspan="1" colspan="1">2 (8.3)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.491*</td></tr><tr><td rowspan="1" colspan="1">Insurance</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Private</td><td rowspan="1" colspan="1">12 (50.0)</td><td rowspan="1" colspan="1">10 (45.5)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.0002</td><td rowspan="1" colspan="1">0.758</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Medicare</td><td rowspan="1" colspan="1">11 (45.8)</td><td rowspan="1" colspan="1">12 (54.4)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.087</td><td rowspan="1" colspan="1">0.555</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Medicaid</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Uninsured</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Smoking status</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.439*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Current</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (9.1)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Former</td><td rowspan="1" colspan="1">6 (25.0)</td><td rowspan="1" colspan="1">5 (22.7)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Never</td><td rowspan="1" colspan="1">18 (75.0)</td><td rowspan="1" colspan="1">15 (68.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">History of fragility fracture</td><td rowspan="1" colspan="1">19 (79.2)</td><td rowspan="1" colspan="1">16 (72.7)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.027</td><td rowspan="1" colspan="1">0.869</td></tr><tr><td rowspan="1" colspan="1">Assistive device</td><td rowspan="1" colspan="1">3 (12.5)</td><td rowspan="1" colspan="1">3 (13.6)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Cognitive dysfunction</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr><td rowspan="1" colspan="1">Current regular exercise</td><td rowspan="1" colspan="1">23 (95.8)</td><td rowspan="1" colspan="1">17 (77.3)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.090*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Calcium supplement</td><td rowspan="1" colspan="1">14 (58.3)</td><td rowspan="1" colspan="1">9 (40.9)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.784</td><td rowspan="1" colspan="1">0.376</td></tr><tr><td rowspan="1" colspan="1">Vitamin D supplement</td><td rowspan="1" colspan="1">18 (75.0)</td><td rowspan="1" colspan="1">17 (77.3)</td><td rowspan="1" colspan="1">X<sup>2</sup> &#x0003c;0.001</td><td rowspan="1" colspan="1">1</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Previous bone medication</td><td rowspan="1" colspan="1">12 (50.0)</td><td rowspan="1" colspan="1">8 (36.4)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.402</td><td rowspan="1" colspan="1">0.526</td></tr><tr><td rowspan="1" colspan="1">Chronic kidney disease</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (4.5)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.478*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Liver disease</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">1*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0; Diet controlled</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0; Medication controlled</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Other</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">1 (4.5)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; None</td><td rowspan="1" colspan="1">22 (91.7)</td><td rowspan="1" colspan="1">21 (95.5)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">History of cancer</td><td rowspan="1" colspan="1">5 (20.8)</td><td rowspan="1" colspan="1">3 (13.6)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.702*</td></tr><tr><td rowspan="1" colspan="1">Thyroid disease</td><td rowspan="1" colspan="1">2 (8.3)</td><td rowspan="1" colspan="1">3 (13.6)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.659*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Autoimmune disease</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">0.223*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Rheumatoid arthritis</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (9.1)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Systemic lupus</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Other</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Family history of osteoporosis</td><td rowspan="1" colspan="1">15 (62.5)</td><td rowspan="1" colspan="1">11 (50.0)</td><td rowspan="1" colspan="1">X<sup>2</sup> = 0.310</td><td rowspan="1" colspan="1">0.578</td></tr><tr><td rowspan="1" colspan="1">Total number of visits</td><td rowspan="1" colspan="1">7.0 &#x000b1; 2.5</td><td rowspan="1" colspan="1">8.1 &#x000b1; 4.0</td><td rowspan="1" colspan="1">t-score = -1.146</td><td rowspan="1" colspan="1">0.260</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Medication</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">X<sup>2</sup> = 2.239</td><td rowspan="1" colspan="1">0.135</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Teriparatide</td><td rowspan="1" colspan="1">4 (16.7)</td><td rowspan="1" colspan="1">9 (40.9)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Abaloparatide</td><td rowspan="1" colspan="1">20 (83.3)</td><td rowspan="1" colspan="1">13 (59.1)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Reason for non-compliance</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Financial</td><td rowspan="1" colspan="1">4 (16.7)</td><td rowspan="1" colspan="1">10 (45.5)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Patient decision</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">3 (13.6)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Provider switched</td><td rowspan="1" colspan="1">1 (4.2)</td><td rowspan="1" colspan="1">4 (18.2)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0; Side effects</td><td rowspan="1" colspan="1">19 (79.2)</td><td rowspan="1" colspan="1">5 (22.7)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>There were no differences in fracture rates during/after medication therapy between compliant and non-compliant patients, early and late non-compliant patients, or teriparatide and abaloparatide patients (Table <xref rid="TAB4" ref-type="table">4</xref>).</p><table-wrap position="float" id="TAB4"><label>Table 4</label><caption><title>Fracture rates during/after medication therapy</title><p>All data presented as n (%).</p><p>* indicates Fisher&#x02019;s exact test; N/A: not applicable</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Comparison Group</td><td rowspan="1" colspan="1">Fracture Rate</td><td rowspan="1" colspan="1">P-value</td></tr><tr><td rowspan="1" colspan="1">All patients</td><td rowspan="1" colspan="1">9/100 (9.0%)</td><td rowspan="1" colspan="1">N/A</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Non-compliant</td><td rowspan="1" colspan="1">7/46 (15.2%)</td><td rowspan="2" colspan="1">0.076*</td></tr><tr><td rowspan="1" colspan="1">Compliant</td><td rowspan="1" colspan="1">2/54 (3.7%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Early non-compliance</td><td rowspan="1" colspan="1">4/24 (16.7%)</td><td rowspan="2" colspan="1">1.000*</td></tr><tr><td rowspan="1" colspan="1">Late non-compliance</td><td rowspan="1" colspan="1">3/22 (13.6%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Teriparatide</td><td rowspan="1" colspan="1">3/42 (7.1%)</td><td rowspan="1" colspan="1">0.730*</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Over the planned two-year course of treatment for patients treated with abaloparatide or teriparatide, nearly two-thirds of patients were compliant at 12 months&#x000a0;and just over half of patients were compliant for the full 24 months. Patients prescribed teriparatide were more likely to stay compliant and complete the course of treatment, although they were more likely to identify financial issues as the reason for non-compliance, while patients prescribed abaloparatide were more likely to identify side effects as the reason for non-compliance. Patients who became non-compliant in the first three months were more likely to identify side effects as the reason for non-compliance, while patients who became non-compliant later on attributed this to financial issues. There were no differences in fracture rates between groups throughout the study, although there was a trend toward&#x000a0;increased fracture rates in non-compliant patients.</p><p>Rates of compliance with osteoporosis medication can vary widely and are influenced by many factors. Compared with bisphosphonate medications and other antiresorptive agents for osteoporosis treatment, patients prescribed anabolic agents often have better medication compliance [<xref rid="REF10" ref-type="bibr">10</xref>,<xref rid="REF14" ref-type="bibr">14</xref>]. Anabolic agents are also typically reserved for patients with osteoporosis at high risk for fracture, unlike other medications that have a wider indication, which may influence compliance due to increased patient motivation [<xref rid="REF11" ref-type="bibr">11</xref>,<xref rid="REF15" ref-type="bibr">15</xref>]. A study by Durden et al. found that patients prescribed an injectable osteoporosis medication were more likely to be compliant compared to patients prescribed an oral medication, although the overall rate of compliance with any medication was low at 20-41% over two years [<xref rid="REF10" ref-type="bibr">10</xref>]. In a large-scale study of medication compliance with osteoporosis medications, Reyes et al. found that the one-year compliance with teriparatide was 58% and dropped to 19% at two years, while patients taking alendronate had 48% compliance at one year and 29% at two years [<xref rid="REF14" ref-type="bibr">14</xref>]. In a recent study by Gold et al., nearly 65% of patients&#x000a0;prescribed abaloparatide completed the course of treatment [<xref rid="REF6" ref-type="bibr">6</xref>]. In a meta-analysis by Koller et al., patients taking teriparatide had a weighted average compliance of 48% at two years [<xref rid="REF13" ref-type="bibr">13</xref>]. In comparison, patients in our study had relatively high compliance, with 54% of patients completing the full two-year course of treatment. When comparing patients taking teriparatide with patients taking abaloparatide, patients taking teriparatide were more likely to remain compliant for the duration of treatment.&#x000a0;</p><p>It is important to identify reasons for patient non-compliance with osteoporosis medications in order to adequately address this issue. Gastrointestinal (GI) side effects are commonly associated with oral osteoporosis medications, particularly bisphosphates, and these symptoms are often cited as a reason for discontinuation of these medications [<xref rid="REF8" ref-type="bibr">8</xref>,<xref rid="REF16" ref-type="bibr">16</xref>]. The anabolic agents currently in the market, including teriparatide and abaloparatide, are injectable medications&#x000a0;and do not typically cause high levels of GI symptoms that can be experienced with oral medications [<xref rid="REF17" ref-type="bibr">17</xref>]. Woo et al. found that GI symptoms were a significant risk factor for early discontinuation of osteoporosis treatment [<xref rid="REF16" ref-type="bibr">16</xref>]. Common side effects associated with teriparatide and abaloparatide include injection site reactions, palpitations, tachycardia, nausea, headache, dizziness, and extremity pain [<xref rid="REF18" ref-type="bibr">18</xref>-<xref rid="REF20" ref-type="bibr">20</xref>]. While this study did not specify the type of side effect, approximately one-quarter of patients in the study attributed medication side effects as the reason for non-compliance. Financial considerations and medication costs can also be important factors to consider. In a study by Deng et al., of nearly 700 patients prescribed a variety of osteoporosis medications, approximately 8% of patients discontinued medication due to financial concerns [<xref rid="REF9" ref-type="bibr">9</xref>]. In a study looking specifically at abaloparatide compliance, Gold et al. found that 31% of patients discontinued treatment due to financial concerns [<xref rid="REF6" ref-type="bibr">6</xref>]. Of note, the United States patent for teriparatide expired in 2019, and biosimilar medication became available, which may have affected medication price and industry support (i.e., sample medication availability) [<xref rid="REF21" ref-type="bibr">21</xref>,<xref rid="REF22" ref-type="bibr">22</xref>]. Similarly, this study found a similar rate of non-compliance due to financial concerns, with just over 30% of patients reporting that as the reason for non-compliance.</p><p>Given that osteoporosis medications are prescribed in order to decrease fracture risk, examining the rate of fractures for patients taking these medications is vital. Burge et al. found that in a large administrative database study, fracture rates overall and specifically vertebral, nonvertebral, and hip fracture rates decreased as adherence to teriparatide use increased [<xref rid="REF23" ref-type="bibr">23</xref>]. In a meta-analysis by Chen et al., adherence to teriparatide use decreased the rate of all fractures by 28%, decreased the rate of hip fractures by 49%, and decreased the rate of nonvertebral fractures by 26% [<xref rid="REF12" ref-type="bibr">12</xref>]. In a study by Keshishian et al. of female Medicare enrollees, patients who had low adherence to osteoporosis medication had a 32% increased risk for hip or pelvis fracture and a 34% increased risk for vertebral fracture compared to high adherence patients [<xref rid="REF24" ref-type="bibr">24</xref>]. Patients in this study who were non-compliant with medication had approximately four times the risk of fracture&#x000a0;compared to compliant patients; however, this result did not reach statistical significance.</p><p>There are a number of methods that have been investigated in order to increase compliance with osteoporosis medications. A study by Sato et al. found that patients prescribed teriparatide who were also enrolled in a patient support program had higher rates of compliance than those who were&#x000a0;not [<xref rid="REF25" ref-type="bibr">25</xref>]. Cheng et al. found that patients using a mobile health platform were able to effectively increase&#x000a0;their knowledge and compliance regarding osteoporosis [<xref rid="REF26" ref-type="bibr">26</xref>]. van Maren et al. found that patient compliance with teriparatide increased after the introduction of a patient education and support program [<xref rid="REF27" ref-type="bibr">27</xref>]. While this study did not implement any medication-specific patient support programs, compliant patients had, on average, one additional visit to the osteoporosis clinic than non-compliant patients, although this was not statistically significant.</p><p>This study does need to be considered in light of its limitations.&#x000a0;It is a retrospective study from a single institution, and the results may not be comparable to a wider patient population. The retrospective nature of the study also introduces inherent selection bias, although we included all patients prescribed abaloparatide or teriparatide through this osteoporosis clinic. Medication selection was determined by patient and provider discussion and relied on several variables, including insurance coverage, sample medication availability, and patient and provider preference. The sample size was relatively small&#x000a0;and the fracture rate was low overall, which may leave the study underpowered to detect significant differences between groups. Because we collected data directly from the clinic's medical records, we gathered substantial information regarding treatment patterns and compliance, including reasons for non-compliance, which may provide further insight to improve compliance in the future.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>More than half of the patients prescribed teriparatide and abaloparatide in this study completed the full two-year course of treatment, and the average duration of treatment exceeded 15 months. The overall fracture rate during and after treatment was low. Patients who were prescribed teriparatide and those who became non-compliant within three months of initiating treatment were more likely to cite financial concerns as the reason for non-compliance. Patients who were prescribed abaloparatide and those who became non-compliant more than three months after initiating treatment were more likely to report side effects as the reason for non-compliance. Additional studies are needed to further evaluate factors contributing to non-compliance and methods for improving patient compliance while taking osteoporosis medications.&#x000a0;</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study. WIRB-Copernicus Group (WCG) Institutional Review Board (IRB) issued approval N/A. WCG IRB approved a request for a waiver of authorization for use and disclosure of protected health information.</p><p><bold>Animal subjects:</bold> All authors have confirmed that this study did not involve animal subjects or tissue.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> Christina Morganti declare(s) royalties and publishing royalties, financial and material support from Milliman Care Guidelines (MCG) Health.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Andrea H. Johnson, Justin J. Turcotte, Christina Morganti</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Andrea H. Johnson, Jane C. Brennan, Daniel Boudani, Justin J. Turcotte, Gerald Kidd, Lauren Chapa</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Andrea H. Johnson, Jane C. Brennan</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Andrea H. Johnson, Jane C. Brennan, Daniel Boudani, Justin J. Turcotte, Christina Morganti, Gerald Kidd, Lauren Chapa</p><p><bold>Supervision:</bold>&#x000a0; Andrea H. Johnson, Justin J. Turcotte, Christina Morganti</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>The clinician's guide to prevention and treatment of osteoporosis</article-title><source>Osteoporos Int</source><person-group>
<name><surname>LeBoff</surname><given-names>MS</given-names></name>
<name><surname>Greenspan</surname><given-names>SL</given-names></name>
<name><surname>Insogna</surname><given-names>KL</given-names></name>
<name><surname>Lewiecki</surname><given-names>EM</given-names></name>
<name><surname>Saag</surname><given-names>KG</given-names></name>
<name><surname>Singer</surname><given-names>AJ</given-names></name>
<name><surname>Siris</surname><given-names>ES</given-names></name>
</person-group><fpage>2049</fpage><lpage>2102</lpage><volume>33</volume><year>2022</year><pub-id pub-id-type="pmid">35478046</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update</article-title><source>Endocr Pract</source><person-group>
<name><surname>Camacho</surname><given-names>PM</given-names></name>
<name><surname>Petak</surname><given-names>SM</given-names></name>
<name><surname>Binkley</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>1</fpage><lpage>46</lpage><volume>26</volume><year>2020</year></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Economic burden of osteoporosis-related fractures in the US medicare population</article-title><source>Ann Pharmacother</source><person-group>
<name><surname>Williams</surname><given-names>SA</given-names></name>
<name><surname>Daigle</surname><given-names>SG</given-names></name>
<name><surname>Weiss</surname><given-names>R</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Arora</surname><given-names>T</given-names></name>
<name><surname>Curtis</surname><given-names>JR</given-names></name>
</person-group><fpage>821</fpage><lpage>829</lpage><volume>55</volume><year>2021</year><pub-id pub-id-type="pmid">33148010</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States</article-title><source>Mayo Clin Proc</source><person-group>
<name><surname>Singer</surname><given-names>A</given-names></name>
<name><surname>Exuzides</surname><given-names>A</given-names></name>
<name><surname>Spangler</surname><given-names>L</given-names></name>
<etal/>
</person-group><fpage>53</fpage><lpage>62</lpage><volume>90</volume><year>2015</year><pub-id pub-id-type="pmid">25481833</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Addressing the crisis in the treatment of osteoporosis: a path forward</article-title><source>J Bone Miner Res</source><person-group>
<name><surname>Khosla</surname><given-names>S</given-names></name>
<name><surname>Cauley</surname><given-names>JA</given-names></name>
<name><surname>Compston</surname><given-names>J</given-names></name>
<name><surname>Kiel</surname><given-names>DP</given-names></name>
<name><surname>Rosen</surname><given-names>C</given-names></name>
<name><surname>Saag</surname><given-names>KG</given-names></name>
<name><surname>Shane</surname><given-names>E</given-names></name>
</person-group><fpage>424</fpage><lpage>430</lpage><volume>32</volume><year>2017</year><pub-id pub-id-type="pmid">28099754</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study</article-title><source>Osteoporos Int</source><person-group>
<name><surname>Gold</surname><given-names>DT</given-names></name>
<name><surname>Beckett</surname><given-names>T</given-names></name>
<name><surname>Deal</surname><given-names>C</given-names></name>
<etal/>
</person-group><fpage>1407</fpage><lpage>1415</lpage><volume>35</volume><year>2024</year><pub-id pub-id-type="pmid">38653862</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Healthcare professionals' perspectives and experiences of osteoporosis medication treatment: a qualitative systematic review</article-title><source>Arch Osteoporos</source><person-group>
<name><surname>Rezae</surname><given-names>F</given-names></name>
<name><surname>Kelly</surname><given-names>A</given-names></name>
<name><surname>Dey</surname><given-names>S</given-names></name>
<name><surname>Moles</surname><given-names>R</given-names></name>
<name><surname>Carter</surname><given-names>S</given-names></name>
</person-group><fpage>8</fpage><volume>19</volume><year>2024</year><pub-id pub-id-type="pmid">38191760</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries</article-title><source>BMC Musculoskelet Disord</source><person-group>
<name><surname>Yun</surname><given-names>H</given-names></name>
<name><surname>Curtis</surname><given-names>JR</given-names></name>
<name><surname>Guo</surname><given-names>L</given-names></name>
<etal/>
</person-group><fpage>112</fpage><volume>15</volume><year>2014</year><pub-id pub-id-type="pmid">24684864</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Predictors for self-discontinuation of anti-osteoporosis medication: a hospital-based real-world study</article-title><source>PLoS One</source><person-group>
<name><surname>Deng</surname><given-names>YL</given-names></name>
<name><surname>Hsu</surname><given-names>CS</given-names></name>
<name><surname>Hsu</surname><given-names>CY</given-names></name>
<etal/>
</person-group><volume>17</volume><year>2022</year></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States</article-title><source>Arch Osteoporos</source><person-group>
<name><surname>Durden</surname><given-names>E</given-names></name>
<name><surname>Pinto</surname><given-names>L</given-names></name>
<name><surname>Lopez-Gonzalez</surname><given-names>L</given-names></name>
<name><surname>Juneau</surname><given-names>P</given-names></name>
<name><surname>Barron</surname><given-names>R</given-names></name>
</person-group><fpage>22</fpage><volume>12</volume><year>2017</year><pub-id pub-id-type="pmid">28243883</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Abaloparatide real-world patient experience study</article-title><source>JBMR Plus</source><person-group>
<name><surname>Gold</surname><given-names>DT</given-names></name>
<name><surname>Weiss</surname><given-names>R</given-names></name>
<name><surname>Beckett</surname><given-names>T</given-names></name>
<etal/>
</person-group><volume>5</volume><year>2021</year></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis</article-title><source>Horm Metab Res</source><person-group>
<name><surname>Chen</surname><given-names>Q</given-names></name>
<name><surname>Guo</surname><given-names>M</given-names></name>
<name><surname>Ma</surname><given-names>X</given-names></name>
<name><surname>Pu</surname><given-names>Y</given-names></name>
<name><surname>Long</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
</person-group><fpage>785</fpage><lpage>791</lpage><volume>51</volume><year>2019</year><pub-id pub-id-type="pmid">31826274</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Persistence and adherence to parenteral osteoporosis therapies: a systematic review</article-title><source>Osteoporos Int</source><person-group>
<name><surname>Koller</surname><given-names>G</given-names></name>
<name><surname>Goetz</surname><given-names>V</given-names></name>
<name><surname>Vandermeer</surname><given-names>B</given-names></name>
<name><surname>Homik</surname><given-names>J</given-names></name>
<name><surname>McAlister</surname><given-names>FA</given-names></name>
<name><surname>Kendler</surname><given-names>D</given-names></name>
<name><surname>Ye</surname><given-names>C</given-names></name>
</person-group><fpage>2093</fpage><lpage>2102</lpage><volume>31</volume><year>2020</year><pub-id pub-id-type="pmid">32613409</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study</article-title><source>Osteoporos Int</source><person-group>
<name><surname>Reyes</surname><given-names>C</given-names></name>
<name><surname>Tebe</surname><given-names>C</given-names></name>
<name><surname>Martinez-Laguna</surname><given-names>D</given-names></name>
<name><surname>Ali</surname><given-names>MS</given-names></name>
<name><surname>Soria-Castro</surname><given-names>A</given-names></name>
<name><surname>Carbonell</surname><given-names>C</given-names></name>
<name><surname>Prieto-Alhambra</surname><given-names>D</given-names></name>
</person-group><fpage>2997</fpage><lpage>3004</lpage><volume>28</volume><year>2017</year><pub-id pub-id-type="pmid">28714038</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications</article-title><source>Bone Rep</source><person-group>
<name><surname>Hayes</surname><given-names>KN</given-names></name>
<name><surname>Cadarette</surname><given-names>SM</given-names></name>
<name><surname>Burden</surname><given-names>AM</given-names></name>
</person-group><volume>20</volume><year>2024</year></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study</article-title><source>Curr Med Res Opin</source><person-group>
<name><surname>Woo</surname><given-names>C</given-names></name>
<name><surname>Gao</surname><given-names>G</given-names></name>
<name><surname>Wade</surname><given-names>S</given-names></name>
<name><surname>Hochberg</surname><given-names>MC</given-names></name>
</person-group><fpage>1003</fpage><lpage>1009</lpage><volume>26</volume><year>2010</year><pub-id pub-id-type="pmid">20201623</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study</article-title><source>Osteoporos Int</source><person-group>
<name><surname>Modi</surname><given-names>A</given-names></name>
<name><surname>Sen</surname><given-names>S</given-names></name>
<name><surname>Adachi</surname><given-names>JD</given-names></name>
<etal/>
</person-group><fpage>1227</fpage><lpage>1238</lpage><volume>27</volume><year>2016</year><pub-id pub-id-type="pmid">26637321</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Latest on anabolic agents for osteoporosis treatment</article-title><source>Endocrinol Metab Clin North Am</source><person-group>
<name><surname>di Filippo</surname><given-names>L</given-names></name>
<name><surname>Rosen</surname><given-names>CJ</given-names></name>
</person-group><fpage>513</fpage><lpage>523</lpage><volume>53</volume><year>2024</year><pub-id pub-id-type="pmid">39448133</pub-id>
</element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Arch Osteoporos</source><person-group>
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Ge</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>B</given-names></name>
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Zou</surname><given-names>T</given-names></name>
<name><surname>Chen</surname><given-names>Q</given-names></name>
</person-group><fpage>89</fpage><volume>19</volume><year>2024</year><pub-id pub-id-type="pmid">39312040</pub-id>
</element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>PTH analogues and osteoporotic fractures</article-title><source>Expert Opin Biol Ther</source><person-group>
<name><surname>Verhaar</surname><given-names>HJ</given-names></name>
<name><surname>Lems</surname><given-names>WF</given-names></name>
</person-group><fpage>1387</fpage><lpage>1394</lpage><volume>10</volume><year>2010</year><pub-id pub-id-type="pmid">20629581</pub-id>
</element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Drug prices after patent expirations in high-income countries and implications for cost-effectiveness analyses</article-title><source>JAMA Health Forum</source><person-group>
<name><surname>Serra-Burriel</surname><given-names>M</given-names></name>
<name><surname>Martin-Bassols</surname><given-names>N</given-names></name>
<name><surname>Per&#x000e9;nyi</surname><given-names>G</given-names></name>
<name><surname>Vokinger</surname><given-names>KN</given-names></name>
</person-group><volume>5</volume><year>2024</year></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>The impact of patent expiry on drug prices: a systematic literature review</article-title><source>Appl Health Econ Health Policy</source><person-group>
<name><surname>Vondeling</surname><given-names>GT</given-names></name>
<name><surname>Cao</surname><given-names>Q</given-names></name>
<name><surname>Postma</surname><given-names>MJ</given-names></name>
<name><surname>Rozenbaum</surname><given-names>MH</given-names></name>
</person-group><fpage>653</fpage><lpage>660</lpage><volume>16</volume><year>2018</year><pub-id pub-id-type="pmid">30019138</pub-id>
</element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States</article-title><source>Osteoporos Int</source><person-group>
<name><surname>Burge</surname><given-names>RT</given-names></name>
<name><surname>Disch</surname><given-names>DP</given-names></name>
<name><surname>Gelwicks</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Krege</surname><given-names>JH</given-names></name>
</person-group><fpage>799</fpage><lpage>809</lpage><volume>28</volume><year>2017</year><pub-id pub-id-type="pmid">28028555</pub-id>
</element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. medicare population</article-title><source>J Manag Care Spec Pharm</source><person-group>
<name><surname>Keshishian</surname><given-names>A</given-names></name>
<name><surname>Boytsov</surname><given-names>N</given-names></name>
<name><surname>Burge</surname><given-names>R</given-names></name>
<etal/>
</person-group><fpage>1178</fpage><lpage>1190</lpage><volume>23</volume><year>2017</year><pub-id pub-id-type="pmid">29083977</pub-id>
</element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS)</article-title><source>Arch Osteoporos</source><person-group>
<name><surname>Sato</surname><given-names>M</given-names></name>
<name><surname>Tsujimoto</surname><given-names>M</given-names></name>
<name><surname>Kajimoto</surname><given-names>K</given-names></name>
<name><surname>Uetake</surname><given-names>H</given-names></name>
<name><surname>Shimoda</surname><given-names>H</given-names></name>
<name><surname>Fujiwara</surname><given-names>S</given-names></name>
</person-group><fpage>74</fpage><volume>13</volume><year>2018</year><pub-id pub-id-type="pmid">29978364</pub-id>
</element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Effectiveness of mobile health platform-based continuity of care in osteoporosis prevention and treatment</article-title><source>Altern Ther Health Med</source><person-group>
<name><surname>Cheng</surname><given-names>WP</given-names></name>
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Shen</surname><given-names>D</given-names></name>
<name><surname>Xu</surname><given-names>GH</given-names></name>
<name><surname>Jiang</surname><given-names>JW</given-names></name>
<name><surname>Gu</surname><given-names>HY</given-names></name>
</person-group><fpage>144</fpage><lpage>149</lpage><volume>30</volume><year>2024</year><uri xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/38466062">https://www.ncbi.nlm.nih.gov/pubmed/38466062</uri></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program</article-title><source>Osteoporos Int</source><person-group>
<name><surname>van Maren</surname><given-names>MA</given-names></name>
<name><surname>Wyers</surname><given-names>CE</given-names></name>
<name><surname>Driessen</surname><given-names>JH</given-names></name>
<etal/>
</person-group><fpage>1837</fpage><lpage>1844</lpage><volume>30</volume><year>2019</year><pub-id pub-id-type="pmid">31321446</pub-id>
</element-citation></ref></ref-list></back></article>